of Company Secretary, the Establishment of New Subsidiary and Subsidiary to Purchase Drug Care Company Limited (Revise no. 2) 10/11/2021 09:27 Notification of the resignation of Chairman of the Audit

recognition Drug license Manufacturing service (OEM) Contracts with a customer ▪ บรษัิทยาท าสญัญาขายทะเบยีนต ารับยาทีไ่ดข้ ึน้ ทะเบยีนยากบั อย. แลว้ ใหล้กูคา้ ▪ ลกูคา้ยังไมไ่ดรั้บโอน ทะเบยีนต ารับยาตาม กฎหมาย

Committee, Appointment of Audit Committee, Appointment of Company Secretary, the Establishment of New Subsidiary and Subsidiary to Purchase Drug Care Company Limited (Revise no. 2) 10/11/2021 09:27

international sales declined dramatically at 46.03% compared to the same period of the previous year. One of the issues was the delayed product delivery after the license was issued from China Food and Drug

issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures

the issuer’s core business. In any event, the issuer must not operate business in such a way that involves severely illegal business. For example, human trafficking, drug production or smuggling, or

, e.g., supermarket, food and restaurants (only for takeaway), drug stores.  Online sales continued to grow remarkably by 150.0% YoY.  Gross profit margin from sale of goods improved outstandingly to

baht or 6. 56 percent from the previous year, mainly due to a decrease of drug and medical supply cost since the volume of general patients and social security patients decreased. Besides, the Company

involves severely illegal business. For example, human trafficking, drug smuggling or money laundering etc. Moreover, the issuer must not act in violation or non-compliance with the law, which may cause

inventory on lower- margins from sales. Total expenses were Baht 450.0 million, decreased by 5.9% compared to same quarter last year due to measures taken up to control expenses. As a result, the Company